Literature DB >> 6542448

Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen.

P M Plezia, D S Alberts, J Kessler, M S Aapro, V Graham, E A Surwit.   

Abstract

A five-drug parenteral antiemetic regimen was administered to 17 patients experiencing intractable vomiting following treatment with cisplatin-containing combination chemotherapy. The five-drug treatment consisted of metoclopramide (1 mg/kg iv), diphenhydramine (50 mg im), dexamethasone (20 mg iv), diazepam (5 mg iv), and thiethylperazine (10 mg im), given together at the initiation of the regimen and repeated on a predefined schedule. The number of emetic episodes, duration of nausea and vomiting, and adverse effects were recorded by trained observers. In addition, all patients completed standardized evaluation forms on the day after treatment. Thirteen patients (76%) remained free of vomiting and three (18%) had only one emesis after beginning the study treatment. No serious toxicity was encountered. We conclude that intractable vomiting induced by cisplatin-based combination chemotherapy can be successfully terminated with an aggressive parenteral antiemetic regimen.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6542448

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

1.  An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patients.

Authors:  J F Kessler; D S Alberts; P M Plezia; V Wilson; J Chase; M Aapro; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting.

Authors:  F Roila; C Basurto; V Minotti; E Ballatori; M Tonato
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Acupuncture prophylaxis of cancer chemotherapy-induced sickness.

Authors:  J W Dundee; R G Ghaly; K T Fitzpatrick; W P Abram; G A Lynch
Journal:  J R Soc Med       Date:  1989-05       Impact factor: 18.000

4.  Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

Authors:  J Cassidy; V Raina; C Lewis; L Adams; M Soukop; W G Rapeport; B D Zussman; E M Rankin; S B Kaye
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

Review 5.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.